Over half of the ducks vaccinated against avian influenza in France are still not fully protected against the virus.
A model from France’s agency for human and animal health, Anses, shows that only 40-45% of ducks achieve full protection from a complete vaccination scheme. The rest are either partially protected (due to ongoing vaccination) or have waning immunity.
In fact, Anses’ experimental estimates indicate that protection levels in ducks over 10 weeks old decline over time. To counter this, foie gras ducks, which are typically held for an average of 16 weeks, receive a third vaccine dose.
In October 2023, France became the first European country to mandate vaccination for all ducks on farms with more than 250 birds, following devastating avian influenza outbreaks in previous winters.
By 31 March 2024, 51 million doses had been administered, covering over 95% of ducks on affected farms. Most received 2 doses: the first at 10 days of age and the second about 20 days later. This protocol has been followed in subsequent vaccination campaigns.
To calculate the effectiveness of those massive and costly campaigns, experts of Anses developed a model based on practical information collected in the field by the state’s directorate-general for agriculture.
“From the percentages of livestock holdings fully or partially protected, one can assume a certain level of protection for the whole duck population. Observing the vaccination rules by the production sectors is essential to optimise that protection,” Morgane Salines, scientific expert for epidemiology, health and welfare at Anses said.
Colleague Béatrice Grasland, head of avian virology and immunology, adds: “Vaccination doesn’t stop infection by the virus, but it limits the clinical signs and diminishes the excretion of the virus by infected animals, thus slowing down a further spread within the farm or to other holdings.”
The model also enables testing of vaccination scenarios not yet in use. One option is to skip vaccination during periods of lower avian influenza risk to reduce high costs for the state and poultry sector. However, Anses deems this unviable. Without summer vaccination, immunity develops too slowly, leaving ducks unprotected during the high-risk autumn and winter periods.
Facts Only
France mandated avian influenza vaccination for all ducks on farms with more than 250 birds in October 2023.
By 31 March 2024, 51 million vaccine doses had been administered, covering over 95% of ducks on affected farms.
The standard vaccination protocol involves two doses: the first at 10 days of age and the second about 20 days later.
Foie gras ducks, typically reared for 16 weeks, receive a third vaccine dose due to declining immunity over time.
Anses, France’s agency for human and animal health, estimates that only 40-45% of ducks achieve full protection from vaccination.
Protection levels decline in ducks over 10 weeks old, according to experimental estimates.
Vaccination does not prevent infection but reduces clinical signs and viral excretion, slowing transmission.
Anses developed a model to assess vaccination effectiveness based on field data from the directorate-general for agriculture.
Skipping summer vaccinations is deemed unviable, as it would leave ducks unprotected during high-risk autumn and winter periods.
The model allows testing of alternative vaccination scenarios not currently in use.
Morgane Salines and Béatrice Grasland are cited as Anses experts on epidemiology and avian virology, respectively.
France experienced devastating avian influenza outbreaks in previous winters, prompting the vaccination mandate.
Executive Summary
France has implemented a mandatory vaccination program for ducks to combat avian influenza, becoming the first European country to do so in October 2023. By March 2024, over 51 million vaccine doses had been administered, covering more than 95% of ducks on farms with over 250 birds. The standard protocol involves two doses, with a third dose given to foie gras ducks due to their longer rearing period. However, modeling by Anses, France’s agency for human and animal health, reveals that only 40-45% of ducks achieve full protection, with others either partially protected or experiencing waning immunity over time. Experts emphasize that while vaccination does not prevent infection, it reduces clinical symptoms and viral shedding, slowing transmission. The model also suggests that skipping summer vaccinations would leave ducks vulnerable during high-risk autumn and winter months, making such a strategy unviable.
The program’s effectiveness hinges on adherence to vaccination rules, as compliance varies across production sectors. The high cost and logistical challenges of sustained vaccination remain key concerns, but Anses warns that reducing doses during low-risk periods could compromise herd immunity. The initiative reflects France’s proactive stance against avian influenza, which has caused significant outbreaks in previous winters, though the limited protection rates highlight ongoing challenges in disease control.
Full Take
The strongest version of this narrative presents France’s duck vaccination program as a necessary, science-backed response to recurrent avian influenza outbreaks, with Anses providing rigorous modeling to optimize protection. The program’s scale—51 million doses covering 95% of targeted ducks—demonstrates a serious commitment to biosecurity, even as the data reveals limitations in vaccine efficacy. The experts’ transparency about partial protection and the need for booster doses lends credibility, framing vaccination as a harm-reduction tool rather than a silver bullet.
Yet, the narrative also subtly reinforces a paradigm of technological intervention as the primary solution to zoonotic risks, with little discussion of alternative or complementary strategies (e.g., farm density reduction, wildlife management). The focus on compliance and cost implies an underlying tension between public health imperatives and industry viability, a dynamic familiar in agricultural policy. The warning against skipping summer vaccinations, while scientifically justified, could also serve to preempt criticism of the program’s sustainability, aligning with institutional incentives to maintain high vaccination rates.
For human agency, the implications are mixed: farmers gain a tool to mitigate outbreaks, but the reliance on repeated dosing and the admission of incomplete protection may foster dependency on state-led interventions. The second-order costs—financial burdens on taxpayers and producers, potential vaccine resistance, and the ethical trade-offs of intensive poultry farming—remain underexplored. Who benefits most? The poultry industry avoids catastrophic losses, while the state avoids the political fallout of unchecked outbreaks. But the ducks, and the ecosystems they inhabit, bear the biological costs of partial immunity and persistent viral circulation.
Bridge questions: How might this vaccination strategy interact with wild bird populations, which are natural reservoirs for avian influenza? What evidence would shift the cost-benefit analysis toward alternative mitigation measures, such as reducing farm density? And if partial protection is the norm, how should policymakers communicate risks to avoid false confidence in vaccine efficacy?
Counterstrike scan: A bad actor pushing this narrative might exaggerate the program’s success (e.g., "95% coverage = near-total protection") while downplaying the 40-45% full-protection rate, using volume of doses as a proxy for effectiveness. They might also frame opposition as "anti-science" to silence debate about systemic risks. However, the actual content avoids these traps, presenting limitations openly and grounding claims in Anses’ modeling. No structural alignment with manipulation patterns detected.
Patterns detected: none
Sentinel — Human
This analysis suggests that the provided text is likely written by a human journalist.